Table 3 Logistic regression models of the likelihood of better compliance with treatment
Model 1a | Model 2b | ||||||
|---|---|---|---|---|---|---|---|
Variable | 95 % CI for OR | 95 % CI for OR | |||||
Category | OR | (lower -upper) | p-value | OR | (lower-upper) | p-value | |
Sex | |||||||
Female | 1.04 | (0.85–1.26) | 0.721 | ||||
Polypharmacy | |||||||
=<2 (Ref.) | <0.001 | <0.001 | |||||
2–2.6 | 2.11 | (1.51–2.96) | <0.001 | 2.10 | (1.51–2.93) | <0.001 | |
2.7–4.3 | 4.67 | (3.39–6.41) | <0.001 | 4.48 | (3.30–6.10) | <0.001 | |
>4.3 | 8.85 | (6.33–12.35) | <0.001 | 8.20 | (6.02–11.11) | <0.001 | |
Age group | |||||||
Under 35 (Ref.) | 0.389 | ||||||
35–64 | 1.00 | (0.75–1.33) | 0.991 | ||||
Over 65 | 0.87 | (0.63–1.20) | 0.392 | ||||
Diagnosis recorded | |||||||
None (Ref.) | <0.001 | <0.001 | |||||
Only anxiety | 1.41 | (1.13–1.75) | 0.002 | 1.45 | (1.17–1.80) | <0.001 | |
Only depression | 1.58 | (1.26–1.97) | <0.001 | 1.63 | (1.31–2.03) | <0.001 | |
Ambos | 1.74 | (1.25–2.42) | 0.001 | 1.84 | (1.33–2.54) | <0.001 | |
Drug dispensed | |||||||
Amitriptyline | 0.81 | (0.66–1.00) | 0.047 | ||||
Paroxetine | 0.57 | (0.48–0.68) | <0.001 | 0.57 | (0.48–0.68) | <0.001 | |
Fluoxetine | 1.09 | (0.91–1.30) | 0.335 | ||||
Citalopram | 1.05 | (0.88–1.25) | 0.604 | ||||
Sertraline | 1.11 | (0.93–1.34) | 0.256 | ||||
Venlafaxine | 1.92 | (1.59–2.30) | <0.001 | 1.99 | (1.66–2.39) | <0.001 | |
Clomipramine | 1.78 | (1.40–2.27) | <0.001 | 1.80 | (1.41–2.28) | <0.001 | |
Mirtazapine | 1.39 | (1.10–1.75) | 0.005 | 1.44 | (1.14–1.81) | 0.002 | |
Trazodone | 0.58 | (0.40–0.83) | 0.003 | 0.60 | (0.42–0.85) | 0.005 | |
Maprotiline | 1.61 | (1.07–2.43) | 0.023 | 1.64 | (1.09–2.46) | 0.018 | |
Imipramine | 1.70 | (0.86–3.38) | 0.129 | ||||
Nortriptyline | 1.41 | (0.56–3.52) | 0.462 | ||||
Fluvoxamine | 1.45 | (0.94–2.24) | 0.089 | ||||
Hosmer & Lemeshow test | 0.003 | 0.781 | |||||
Discrimination (Area Under Curve COR) | 0.749 | <0.001 | 0.729 | <0.001 | |||